Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NSPR NASDAQ:NTRB NASDAQ:VANI OTCMKTS:VASO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNSPRInspireMD$2.52-2.3%$2.42$1.99▼$3.80$105.14M0.6102,985 shs58,136 shsNTRBNutriband$6.80-0.7%$7.90$3.72▼$11.78$76.41M1.13194,285 shs70,584 shsVANIVivani Medical$1.27+0.8%$1.34$0.91▼$1.80$74.65M2.99182,381 shs100,366 shsVASOVaso$0.13+3.1%$0.13$0.11▼$0.32$21.81M1.5765,160 shs23,100 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNSPRInspireMD+6.61%-3.37%+9.32%+6.17%-9.79%NTRBNutriband-4.46%-3.66%-13.94%+19.55%+25.69%VANIVivani Medical-8.70%-10.00%-10.00%+20.00%+6.78%VASOVaso-0.08%+6.07%+1.64%-9.75%-47.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNSPRInspireMD3.0239 of 5 stars3.53.00.00.01.14.20.6NTRBNutriband3.2216 of 5 stars3.55.00.00.02.31.70.6VANIVivani Medical3.0833 of 5 stars3.53.00.00.03.33.30.0VASOVaso0.8357 of 5 stars0.05.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNSPRInspireMD 3.00Buy$4.5078.57% UpsideNTRBNutriband 3.00Buy$13.0091.18% UpsideVANIVivani Medical 3.00Buy$4.00214.96% UpsideVASOVaso 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VASO, VANI, NTRB, and NSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.005/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.00(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNSPRInspireMD$7.07M14.88N/AN/A$1.83 per share1.38NTRBNutriband$2.14M35.43N/AN/A$0.58 per share11.72VANIVivani MedicalN/AN/AN/AN/A$0.30 per shareN/AVASOVaso$86.77M0.26$0.01 per share12.27$0.16 per share0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNSPRInspireMD-$19.92M-$0.83N/AN/AN/A-413.96%-69.42%-57.68%N/ANTRBNutriband-$10.48M-$0.90N/AN/AN/A-415.93%-68.25%-60.40%9/2/2025 (Estimated)VANIVivani Medical-$23.49M-$0.43N/AN/AN/AN/A-133.07%-56.50%8/12/2025 (Estimated)VASOVaso$950KN/A0.00∞N/A1.20%3.93%1.37%8/12/2025 (Estimated)Latest VASO, VANI, NTRB, and NSPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/2/2025N/ANTRBNutriband-$0.17N/AN/AN/A$0.71 millionN/A8/12/2025Q2 2025VANIVivani Medical-$0.09N/AN/AN/AN/AN/A5/30/2025Q1 2026NTRBNutriband-$0.13-$0.12+$0.01-$0.12$0.71 million$0.67 million5/15/2025Q1 2025VASOVasoN/A-$0.01N/A-$0.01N/A$19.46 million5/13/2025Q1 2025VANIVivani Medical-$0.10-$0.11-$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNSPRInspireMDN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/AVASOVasoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNSPRInspireMDN/A6.396.05NTRBNutriband0.013.713.48VANIVivani MedicalN/A2.402.40VASOVasoN/A1.521.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNSPRInspireMD44.78%NTRBNutriband19.70%VANIVivani Medical6.78%VASOVasoN/AInsider OwnershipCompanyInsider OwnershipNSPRInspireMD34.06%NTRBNutriband54.09%VANIVivani Medical46.40%VASOVaso44.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNSPRInspireMD5041.72 million18.33 millionOptionableNTRBNutriband1011.15 million5.12 millionNot OptionableVANIVivani Medical2059.24 million31.76 millionOptionableVASOVaso260175.74 million97.54 millionNot OptionableVASO, VANI, NTRB, and NSPR HeadlinesRecent News About These CompaniesFirst Patient Dosed In Clinical Trial Of Therapy For Sickle DiseaseAugust 8, 2025 | msn.comGreece stuns USA to reach women’s water polo World Championship finalJuly 23, 2025 | neoskosmos.comNLevel of physical activity tied to less pain, blood viscosity in SCD: StudyJune 26, 2025 | sicklecellanemianews.comSCorn in a Cup (Elote en Vaso)June 7, 2025 | msn.comOral inhibitor rilzabrutinib granted FDA orphan drug status for SCDJune 5, 2025 | sicklecellanemianews.comSUS FDA grants orphan drug designation to Sanofi’s rilzabrutinib to treat sickle cell diseaseJune 5, 2025 | pharmabiz.comPSanofi Rilzabrutinib gets USFDA orphan drug designation for sickle cell diseaseJune 4, 2025 | medicaldialogues.inMPress Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell diseaseJune 3, 2025 | taiwannews.com.twTSickle cell disease and knee joint pain: Why steriods aren’t always the best optionMay 30, 2025 | punchng.comPVaso Corporation Registered ShsMay 20, 2025 | markets.businessinsider.comVaso Stock Slips Post Q1 Earnings Despite Record Revenue GrowthMay 20, 2025 | zacks.comVaso Corporation Announces Financial Results for First Quarter of 2025May 15, 2025 | globenewswire.comNew tapas and wine bar to open in Nottingham from the team behind MesaMay 6, 2025 | msn.comHe compared him to Justin Bieber, but he got what he deserved in the ringApril 24, 2025 | msn.comThe Zacks Analyst Blog Highlights Apple, Philip Morris International, Sony and VasoApril 21, 2025 | uk.finance.yahoo.comC-Reactive Protein Increases During Menstrual Cycle in Females With Sickle Cell DiseaseApril 18, 2025 | rheumatologyadvisor.comRTop Analyst Reports for Apple, Philip Morris & SonyApril 17, 2025 | finance.yahoo.comShake up your Monday: VASO hosts an electrifying cocktail showdown with top bartendersApril 17, 2025 | myfox28columbus.comMInflammation during menstrual cycle may trigger VOEs: StudyApril 15, 2025 | sicklecellanemianews.comSDangerous 'crises' in sickle cell disease may be amplified by menstrual cycleApril 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVASO, VANI, NTRB, and NSPR Company DescriptionsInspireMD NYSE:NSPR$2.52 -0.06 (-2.33%) Closing price 04:00 PM EasternExtended Trading$2.58 +0.06 (+2.38%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Nutriband NASDAQ:NTRB$6.80 -0.05 (-0.73%) Closing price 04:00 PM EasternExtended Trading$6.67 -0.13 (-1.91%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Vivani Medical NASDAQ:VANI$1.27 +0.01 (+0.79%) Closing price 04:00 PM EasternExtended Trading$1.25 -0.02 (-1.57%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.Vaso OTCMKTS:VASO$0.13 +0.00 (+3.14%) As of 03:14 PM EasternVaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's White House Reset: From Political Storm to a Clearer Sky AST SpaceMobile on Track for Explosive Upside Oklo’s Stock Is Set up for a Correction—Buy It When It Bounces If Qualcomm Holds $145, Its Next Move Could Be Massive Alphabet Reclaims $200 Threshold—Bull Run Reignited? NFL and WWE Land on ESPN—The Impact on Disney and TKO Stocks Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside Apple & Trump: $100B Investment, Tariffs News Push Shares Up 13% Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access